Portola Pharmaceuticals has signed a $50 million loan agreement with Bristol-Myers Squibb and Pfizer providing additional funding for development and clinical studies of AndexXa (andexanet alfa), an investigational compound that is a potential antidote for Factor Xa inhibitors. BMS and Pfizer will each loan Portola $25 million. The principal and interest will be repaid primarily through royalties on AndexXa sales. AndexXa, an FDA-designated Breakthrough Therapy, is in development for p...